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Lisa Sproat,1 Brian Bolwell,2 Lisa Rybicki,3 Robert Dean,2 Ronald Sobecks,2 Brad Pohlman,2
Steven Andresen,2 John Sweetenham,2 Edward Copelan,2 Matt Kalaycio2Vitamin D (VD) deficiency can cause osteomalacia, bone pain, muscle weakness, fatigue, and increased risk of
fracture, and may precipitate or exacerbate osteopenia and osteoporosis. Patients receiving treatment for
acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) may have limited exposure to sunlight
and often experience gastrointestinal side effects that may decrease their ability to maintain an adequate
VD level. We hypothesized that patients with AML and ALL would have a low VD level after allogeneic
hematopoietic cell transplant (HCT), and that these patients would have a high incidence of osteoporosis/
osteopenia. We therefore studied the incidence of low VD level and low bone mineral density after HCT.
Of 289 patients with AML or ALL undergoing HCT between January 1, 2000, and January 31, 2009, at the
Cleveland Clinic, 58 (20.1%) patients had VD testing after HCT. Of these, 52 (89.7%) patients had a low
VD level, and 6 (10.3%) had a normal level. Most patients with VD testing had graft-versus-host disease
(GVHD) and were taking corticosteroids (94.8% and 98.3%, respectively). Of the 49 patients with VD testing
who also had bone mineral density testing, 65% had abnormal (low bone density) results. Only 21% of pa-
tients with VD testing were taking VD supplements prior to testing, and 65% had an elevated parathyroid
hormone level. We found that most patients did not have VD testing after HCT, but those that did were
very likely to have a low level and have low bone mineral density. Those with a low VD level were likely
to have received corticosteroids, have GVHD, and have an elevated parathyroid hormone (PTH) level. Given
the potential morbidity of low VD level, VD deficiency should be considered after HCT. Prospective study of
VD level and its impact on morbidity and mortality after HCT is warranted.
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Vitamin D (VD) deficiency can cause osteomala-
cia, bone pain, muscle weakness, fatigue, and increased
risk of fracture, and may precipitate or exacerbate
osteopenia and osteoporosis. The health problems
potentially caused by VD deficiency are not inconse-
quential. To maintain normal skeletal homeostasis,
calcium and VD are required. VD aids in calcium
absorption from the gastrointestinal tract. If VD levelBanner Blood andMarrowTransplant Program, Phoenix,
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6/j.bbmt.2010.12.704is low, there is decreased calcium absorption leading to
a negative calcium balance. This results in a compensa-
tory rise in parathyroid hormone (PTH), which then
drives excessive bone resorption [1].
Humans attain vitamin D from exposure to sun-
light, diet, or dietary supplements. Very few foods
are significant sources of vitamin D without fortifica-
tion (fortified foods include cereal, orange juice, and
milk products). Causes of VD deficiency include re-
duced skin synthesis, reduced absorption of VD in
the gastrointestinal tract, and inherited or acquired
disorders of VD metabolism. In addition, liver failure
and chronic kidney disease can cause decreased synthe-
sis of VD, and anticonvulsants, glucocorticoids, and
antirejection medications can cause increased catabo-
lism of VD [1].
Patients presenting for allogeneic hematopoietic
cell transplant (HCT)may already have a low VD level
because of decreased exposure to sunlight from pro-
longed hospital stays, limited outdoor activity, and
sunscreen use, and decreased oral intake because of
gastrointestinal treatment toxicity. Current recom-
mendations in those patients who have undergone1079
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reduce risk of secondary cancer [2]. Gastrointestinal
graft-versus-host disease (GVHD) may further limit
absorption of VD after HCT. HCT patients also
receive medications that cause increased breakdown
of VD, and often have impairments of renal and liver
function. Thus, HCT patients are at risk for VD defi-
ciency and the bone abnormalities that result.
It is known that osteoporosis or osteopenia is pres-
ent in 49% of patients before HCT [3] and occurs in
over 50% of patients after HCT [4,5]. Patients with
normal bone mineral density before HCT have
a statistically significant decrease in bone mineral
density afterward [6]. The principal factors leading to
bone loss after HCT are immunosuppressive therapy,
hypogonadism, kidney dysfunction, malabsorption,
radiation therapy, chemotherapy, and cytokine ther-
apy [7,8]. VD deficiency may also play a role in bone
loss, but has not been carefully studied to date in the
HCT population. A case report has been published
describing the impact of VD on bone density after
HCT [9]. Although decreased VD intake after HCT
has been demonstrated [10], VD deficiency may not
be routinely suspected, and its effect on bone mineral
density has not been well demonstrated in HCT
patients.
The current study was undertaken to describe VD
level in patients after HCT and to evaluate the inci-
dence of osteoporosis/osteopenia among those with
a low level. We hypothesized that patients with acute
myelogenous leukemia (AML) and acute lymphoblas-
tic leukemia (ALL) would have low VD level after
HCT, and those patients with a low level would have
a high incidence of low bone density. We therefore
retrospectively studied VD level and bone density
measurements after HCT in patients with acute leuke-
mia to determine the incidence of low VD level and
osteopenia/osteoporosis in this population. Data on
corticosteroid use, diagnosis of GVHD, and PTH
level was also collected.MATERIALS AND METHODS
A total of 289 patients with AML or ALL under-
went myeloblative or nonyeloablative HCT between
January 1, 2000, and January 31, 2009, at theCleveland
Clinic. Patients were treated with a variety of condi-
tioning regimens. Baseline demographic data, disease
characteristics, transplant variables, and outcomes
data were obtained from the transplant database,
which contains prospectively collected data on all pa-
tients who underwent transplantation at our center.
All patients included in this study were treated on pro-
tocols approved by the Cleveland Clinic’s institutional
review board (IRB) and gave signed informed consent
to allow data collection. These data were supple-mented by an IRB-approved retrospective chart review
for posttransplant VD level, VD supplementation at
the time of VD level, PTH level at the time of VD
level, bone density result closest to the time of VD
level (either before or after), diagnosis of GVHD,
and specialty of physician ordering VD level.
OH VD levels were measured by a direct, compet-
itive chemiluminometric immunoassay (CLIA) on the
automated platform Liaison (Diasorin Inc., Vercelli,
Italy). VD levels were categorized as sufficient (.30
pg/mL), insufficient (20-30 pg/mL), or deficient
(\20 pg/mL). PTH levels were determined by a 2-
site sandwich CLIA on the automated platform AD-
VIA Centaur (Siemens Corp., Deerfield, IL). PTH
levels were categorized as normal (10-60 pg/mL), low
(\10 pg/mL), and high (.60 pg/mL). Bone density
exam was performed at the Cleveland Clinic. A total
of 14 bone density scanners by Lunar and Hologic
were used during the time frame of this study. These
scanners were maintained with the required quality as-
sessments and were within normal operating proce-
dures. Each patient result was compared with the
reference database for the manufacturer for diagnosis.
For patients over the age of 50, the World Health Or-
ganization criteria was used to define bone density
(normal bone density 5 T score $ 21.0 , osteopenia
5 T score\21.0 but . 22.5, and osteoporosis 5 T
score\ 22.5 SD. For patients under the age of 50,
theZ-score was used (Z-score#22was considered ab-
normal bone loss). Results were recorded as normal (no
osteopenia, osteoporosis, or abnormal bone loss) or ab-
normal (osteopenia, osteoporosis, or abnormal bone
loss).Statistical Analysis
Among 289 patients, VD testing was assessed rela-
tive to 5 variables: gender, age at transplant, diagnosis
(AML or ALL), transplant type (myeloablative or
reduced-intensity conditioning [RIC]), and year of
transplant. The chi-square test was used to determine
whether VD testing differed by gender, diagnosis, or
transplant type; the Cochran-Armitage trend test was
used to determine whether VD testing was associated
with age or year of transplantation.
Among 58 patients whose VD level was tested,
continuous variables were compared between patients
with normal and low VDL using the Wilcoxon rank
sum test, and categoric variables were compared using
Fisher’s exact test.
The incidence of lowVD level and the incidence of
osteoporosis/osteopenia were estimated using exact
95% binomial confidence intervals (CI) (95% CI).
Analyses were done using SAS software (SAS
Institute, Inc., Cary, NC). All statistical tests were 2
sided, and P# 0.05 was used to indicate statistical sig-
nificance.
Table 1. Patient Demographics
Variable N %
Gender
Female 39 67.2
Male 19 32.8
Age at transplant, years
Mean ± SD 45 ± 13
Median (range) 47 (18-66)
Diagnosis
AML 47 81.0
ALL 11 19.0
Type of transplant
Myeloablative 50 86.2
Nonmyeloablative 8 13.8
Conditioning regimen
Bu/Cy 28 48.3
TBI/VP 12 20.7
TBI/Flu 8 13.8
Bu/Cy/VP 5 8.6
TBI/Cy 3 5.2
TBI/Cy/ECP 1 1.7
TBI/VP/ATG 1 1.7
Donor
Related 31 43.4
Unrelated 27 46.6
Months from transplant to first VD level
Mean ± S.D. 13.8 ± 18.0
Median (range) 5.9 (0.7-90.4)
Taking VD supplement at time
of first VD level
Yes 12 20.7
No 46 79.3
N indicates number of patients; SD, standard deviation; AML, acute
myeloid leukemia; ALL, acute lymphoblastic lymphoma; Bu, busulfan;
Cy, cyclophosphamide; TBI, total-body irradiation; VP, etoposide; Flu,
fludarabine; ECP, extracorporeal photopheresis; ATG, antithymocyte
globulin; VD, vitamin D.
N total 558 patients in whom vitamin D level was assessed.
Biol Blood Marrow Transplant 17:1079-1083, 2011 1081Vitamin D Level after Stem Cell TransplantRESULTS
Among 289 patients, 58 (20.1%) had VD testing
post-HCT. Patients were more likely to have VD test-
ing if they were female (27.7% versus 12.8% in males;
P 5 .002) and if HCT was performed more recently
(P \ .001). The likelihood of testing did not differ
between AML and ALL (P 5 .14) or between myeloa-
blative and RIC transplants (P 5 .40). Older patients
were somewhat more likely to be tested than younger
patients, but this difference was not quite significant
(P 5 .08). Among 58 patients with VD testing, the
mean time from HCT to VD testing was 13.8 6 18.0
months. Testing was ordered most commonly by phy-
sicians in the osteoporosis/metabolic disease clinic
(79.3%) followed by the HCT physician (8.6%),
women’s health exam provider (3.4%), palliative medi-
cine physician (3.4%), inpatient medicine team (1.7%),
pulmonary physician (1.7%), and unknown provider
(1.7%). Fifty-two (89.7%; 95% CI 78.8-96.1) patients
who had VD testing had a low level, and 6 (10.3%)
had a normal level. Of those with a low level, 18 were
insufficient and 34 were deficient. There was no signif-
icant difference between patients with low and normal
VD levels with respect to gender (P5 .16), age at trans-
plant (P5 .84), diagnosis (P5 .32), or type of transplant
(P 5 .0). Patients with low VD level were transplanted
more recently than those with normal VDL (median
2006 versus 2004; P 5 .038). Most patients with VD
testing had GVHD and were taking corticosteroids
(94.8% and 98.3%, respectively). Only 21% of the pa-
tients with VD testing were taking VD supplements
prior to testing. Of the 49 patients with VD testing
who also had bone density testing, 65% (95% CI
50.4-78.3%) had abnormal scans. PTH level was as-
sessed in 38 (66%) of the patients who had VD testing
done.Of thosewhohadPTH level, 26 (68%)had an ab-
normal result. All but 1 of the abnormal PTH levels
were high. Patient demographics are noted in Table 1.DISCUSSION
Morbidity and mortality is a significant limitation
of HCT. Identification of correctable factors, such as
VD deficiency, that could positively impact outcome
are needed. It is known that HCT patients do not in-
gest adequate VD [10], are advised to avoid sun expo-
sure [2], receive immunosuppressive medication, and
can have organ system compromise. Despite having
these risk factors for VD deficiency, HCT patients
are not often routinely screened with VD level or rou-
tinely advised to take VD supplements.
In this study only 20% of HCT patients had VD
level assessed, although 90% the patients tested had
a low level. Only 12% of the patients who had a VD
level assessed were taking VD supplements. Thissuggests that though VD deficiency may not be rou-
tinely suspected in HCT patients, it should be consid-
ered and assessed. Whether HCT patients should
routinely be placed on a VD supplement is not known.
Even healthy individuals living in areas with low sun
exposure require approximately 800-1000 IU of VD
daily to maintain an adequate level [1]. (Although
VD level can vary by time of year, because of limited
sun exposure in Cleveland, Ohio, VD levels were not
compared by date of assessment.) The high incidence
of low VD level in those tested supports further inves-
tigation of VD level in all HCT patients, and the as-
sessment of VD level in all patients who have used
corticosteroids or have a history of GVHD.
The retrospective data presented in this article
supports a small prospective study by Massenkeil and
colleagues [3] who demonstrated low VD levels after
HCT. Their study was conducted to primarily assess
bone mineral density after transplant, but the VD find-
ings were significant. Sixty-seven patients were pro-
spectively evaluated for radiologic and biochemical
changes in bone metabolism with the goal to better
define risk groups for osteoporosis after HCT. They
found that 26/53 (49%) of patients had decreased
bone density before HCT. All patients after HCT
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22/57 (39%) of patients before HCT, and all patients
had low VD level up to 6 months after HCT. The
current study noted that those patients with a low
VD level were likely to have a low bone density. VD
deficiency predisposes patients to a variety of potential
health problems including osteoporosis, which is
already a known complication of HCT. Whether sup-
plementing VD inHCT patients could have prevented
this bone loss can by hypothesized, but it is not known.
Low VD level, corticosteroids, abnormal bone
density exam, and elevated PTH level all indepen-
dently predict for bone health problems. Most patients
in this study who had a PTH level assessed had a high
level. PTH elevation can be caused by VD deficiency,
renal failure, and loop diuretics. It cannot be deter-
mined from this study whether elevated PTH level
was secondary to VD deficiency. VD deficiency could
be secondary to elevated PTH caused by renal insuffi-
ciency or iatrogenic diuretics used during transplanta-
tion. Prospective assessment of VD level and PTH
level throughout transplantation would elucidate the
underlying cause of low VD level and elevated PTH.
Providers other than the HCT physician were the
most likely to check VD level. Testing was ordered
most commonly by physicians in the osteoporosis/
metabolic disease clinic. The Cleveland Clinic has
a bone and metabolic disease clinic for patients who
have or are at risk for low bone density, and HCT
patients are frequently referred there for evaluation.
The reason for referral to this clinic was most likely
recognition of high risk for osteoporosis because of
corticosteroid use (98% of patients with VD level
have received corticosteroids). The retrospective na-
ture of our data prohibits determination of referral
source and reason for referral to this clinic, but it is
likely that it was theHCTphysician. This would imply
that though the HCT physicians were not the most
likely to test VD level, they were adequately evaluating
the bone health of patients after HCT by referring
them to an appropriate subspecialist. Patients were
also more likely to have VD testing if their HCT was
done in more recent years. Practitioners may currently
be more aware of the role VD plays in bone health than
in previous years as VD in now being recognized to
have multisystem effects.
This study was designed to define the incidence of
low VD level after HCT and describe the bone health
in those patients tested. VD supplementation may
have other benefits beyond improving bone health af-
ter HCT. VD levels have been correlated with cancer
incidence and prevention [11]. Vitamin D metabolites
have been studied for use in the treatment of myeloid
leukemia in older adults [12] and relapsed AML [13].
VD also activates the up-regulation of human catheli-
cidin, which has antimicrobial as well as antiendotoxin
activity. Thus, it has been hypothesized that maintain-ing adequate VD level may reduce the incidence and
improve the prognosis in septicemia [14]. A recent
study has shown that VD insufficiency in patients
with non-Hodgkin lymphoma was associated with in-
ferior event-free survival and overall survival [15]. Vi-
tamin D may be a factor that plays a more pivotal role
than only modulating bone health. Via its relationship
to PTH, cellular differentiation, proliferation, and an-
giogenesis, it could potentially be a key factor in ad-
vancing the practice of HCT [16].
Our study confirms a high incidence of VD defi-
ciency after HCT in acute leukemia patients with
GVHD who have taken corticosteroids. These pa-
tients are at risk for low bone density and osteoporotic
bone fracture, and often complain of bone pain, muscle
weakness, and fatigue that may be amenable to VD
supplementation. VD supplementation may be a low
cost, easy to implement addition to routine care after
HCT that might increase quality of life and reduce
HCT-associated morbidity. Further prospective study
of VD and its impact in HCT is warranted.ACKNOWLEDGMENTS
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